$VKTX News

Why Viking Therapeutics’ Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28

Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market

Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know

Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026

Viking Therapeutics (VKTX) Stock Looks Overvalued Next To Its Book Value

Viking Therapeutics Stock What SUNRISE Phase 3 Start Means For VK2735

Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 Years

Canaccord Genuity Maintains Buy on Viking Therapeutics, Lowers Price Target to $106

Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.

Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know

UBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94

Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?

Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity

Viking Therapeutics Initiates SUNRISE Phase 3 Clinical Program For Oral VK2735 Dual Agonist Of GLP-1 And Glucose-Dependent Insulinotropic Polypeptide Receptors

Viking Therapeutics (VKTX) Stock Dropped, So What Is Driving Attention Now?

Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider

Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know

Analyst Predicts 316% Upside for Viking Therapeutics Stock Despite 30%+ Loss in Last 3 Months

Truist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85

Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity